Portal de Periódicos da CAPES

Review of rifaximin as treatment for SIBO and IBS

2009; Taylor & Francis; Volume: 18; Issue: 3 Linguagem: Inglês

10.1517/13543780902780175

1744-7658

Mark Pimentel,

Pediatric Pain Management Techniques

Rifaximin is a broad-range, gastrointestinal-specific antibiotic that demonstrates no clinically relevant bacterial resistance. Therefore, rifaximin may be useful in the treatment of gastrointestinal disorders associated with altered bacterial flora, including irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO).To review rifaximin for treatment of IBS and SIBO.Review of rifaximin clinical trials.Rifaximin improved global symptoms in 33 - 92% of patients and eradicated SIBO in up to 84% of patients with IBS, with results sustained up to 10 weeks post-treatment. Rifaximin caused a lower number of adverse events compared with metronidazole or levofloxacin and may have a more favorable adverse event profile than systemic antibiotics, without clinically relevant antibiotic resistance.